In addition to prioritizing known and well-established PD genes, including SNCA, LRRK2, GBA1, TMEM175 and VPS13C, we identified six genes (FYN, DYRK1A, NOD2, CTSB, SV2C, and ITPKB) emerged as promising targets for drug repurposing or novel therapeutic development. This evidence concerns the gene LRRK2 and Parkinson disease.